{"id":"NCT00996736","sponsor":"University of California, San Francisco","briefTitle":"Mycotic Ulcer Treatment Trial I","officialTitle":"Mycotic Ulcer Treatment Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2009-10-16","resultsPosted":"2013-12-11","lastUpdate":"2018-08-01"},"enrollment":323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Corneal Ulcer","Eye Infections, Fungal"],"interventions":[{"type":"DRUG","name":"Natamycin","otherNames":[]},{"type":"DRUG","name":"Voriconazole","otherNames":[]}],"arms":[{"label":"Topical Natamycin","type":"ACTIVE_COMPARATOR"},{"label":"Topical Voriconazole","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if natamycin or voriconazole results in better visual outcomes in fungal corneal ulcers, especially visual acuity.","primaryOutcome":{"measure":"Best Spectacle-corrected logMAR Visual Acuity","timeFrame":"3 months from enrollment","effectByArm":[{"arm":"Topical Natamycin","deltaMin":0.39,"sd":null},{"arm":"Topical Voriconazole","deltaMin":0.57,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.006"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":3,"countries":["United States","India"]},"refs":{"pmids":["23710492","35024776","28817744","28426856","27787540","27054515","26531051","25764482","23702779"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":162},"commonTop":["Increase in infiltrate size > 50%","Increase in hypopyon (>2mm)","Progressive corneal thinning, <=50% of enrollment thickness"]}}